Calithera Biosciences (CALA) Set to Post Earnings on Tuesday

Calithera Biosciences (OTCMKTS:CALA – Get Free Report) is expected to release its results on Tuesday, November 17th. Analysts expect the company to announce earnings of ($5.5188) per share and revenue of $0.48 million for the quarter.

Calithera Biosciences Stock Performance

OTCMKTS CALA opened at $0.00 on Monday. Calithera Biosciences has a 52-week low of $0.00 and a 52-week high of $0.00.

About Calithera Biosciences

(Get Free Report)

Calithera Biosciences, Inc. was a clinical-stage biotechnology company focused on developing small-molecule therapies that target cancer metabolism. The company’s research centered on metabolic pathways that tumors use to support growth and survival, with the goal of improving outcomes for patients with cancer. Its lead investigational product was telaglenastat (CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. Calithera evaluated telaglenastat in combination with other treatments for cancers including renal cell carcinoma, triple-negative breast cancer and hematologic malignancies.

Read More

Earnings History for Calithera Biosciences (OTCMKTS:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.